FMO3
Flavin-containing monooxygenase 3
Also known as: FMO3_HUMAN, FMOII
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P31513
- Gene
- FMO3
- Ensembl
- ENSG00000007933
- Chromosome
- 1
- Canonical length
- 532 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
Flavin-containing monooxygenases (FMO) are an important class of drug-metabolizing enzymes that catalyze the NADPH-dependent oxygenation of various nitrogen-,sulfur-, and phosphorous-containing xenobiotics such as therapeutic drugs, dietary compounds, pesticides, and other foreign compounds. The human FMO gene family is composed of 5 genes and multiple pseudogenes. FMO members have distinct developmental- and tissue-specific expression patterns. The expression of this FMO3 gene, the major FMO expressed in adult liver, can vary up to 20-fold between individuals. This inter-individual variation in FMO3 expression levels is likely to have significant effects on the rate at which xenobiotics are metabolised and, therefore, is of considerable interest to the pharmaceutical industry. This transmembrane protein localizes to the endoplasmic reticulum of many tissues. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. Mutations in this gene cause the disorder trimethylaminuria (TMAu) which is characterized by the accumulation and excretion of unmetabolized trimethylamine and a distinctive body odor. In healthy individuals, trimethylamine is primarily converted to the non odorous trimethylamine N-oxide.[provided by RefSeq, Jan 2016]
Canonical amino-acid sequenceUniProt
532 residues, UniProt reviewed canonical sequence.
>P31513|FMO3
1 MGKKVAIIGA GVSGLASIRS CLEEGLEPTC FEKSNDIGGL WKFSDHAEEG RASIYKSVFS
61 NSSKEMMCFP DFPFPDDFPN FMHNSKIQEY IIAFAKEKNL LKYIQFKTFV SSVNKHPDFA
121 TTGQWDVTTE RDGKKESAVF DAVMVCSGHH VYPNLPKESF PGLNHFKGKC FHSRDYKEPG
181 VFNGKRVLVV GLGNSGCDIA TELSRTAEQV MISSRSGSWV MSRVWDNGYP WDMLLVTRFG
241 TFLKNNLPTA ISDWLYVKQM NARFKHENYG LMPLNGVLRK EPVFNDELPA SILCGIVSVK
301 PNVKEFTETS AIFEDGTIFE GIDCVIFATG YSFAYPFLDE SIIKSRNNEI ILFKGVFPPL
361 LEKSTIAVIG FVQSLGAAIP TVDLQSRWAA QVIKGTCTLP SMEDMMNDIN EKMEKKRKWF
421 GKSETIQTDY IVYMDELSSF IGAKPNIPWL FLTDPKLAME VYFGPCSPYQ FRLVGPGQWP
481 GARNAILTQW DRSLKPMQTR VVGRLQKPCF FFHWLKLFAI PILLIAVFLV LTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FMO3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 1,050 nTPM
Expression across tissuesHPA
Tissue
- liver: 1,050 nTPM
- adipose tissue: 27 nTPM
- lung: 18 nTPM
- kidney: 13 nTPM
- fallopian tube: 13 nTPM
- adrenal gland: 12 nTPM
Single-cell type
- hepatocytes: 601 nCPM
- respiratory secretory cells: 48 nCPM
- salivary ionocytes: 39 nCPM
- fibro-adipogenic progenitors: 35 nCPM
- respiratory basal cells: 32 nCPM
- pericytes: 31 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- medulla oblongata: 7.2 nTPM
- spinal cord: 4.9 nTPM
- pons: 2.4 nTPM
- thalamus: 2.2 nTPM
- midbrain: 2.1 nTPM
- basal ganglia: 2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FMO3.
Disease | AllUniProt
Conditions FMO3 is implicated in, by any mechanism.
- Trimethylaminuria (TMAU) MIM:602079
Disease | GeneticClinVar
96 pathogenic / likely-pathogenic of 311 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Trimethylaminuria
- FMO3-related disorder
- FMO3 activity, decreased
- See cases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.58
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.16
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- flavin adenine dinucleotide binding
- hypotaurine monooxygenase activity
- N,N-dimethylaniline monooxygenase activity
- NADP binding
- trimethylamine monooxygenase activity
- albendazole monooxygenase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FMO3 as an antibody target. Whether an autoantibody or antibody against FMO3 could matter depends on whether native FMO3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FMO3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FMO3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...